BrainChild Bio Raises $116M Series A on Sept. 8 to Fund Phase 2 B7-H3 CAR T Trial for DIPG
BrainChild Bio raised $116 million in a Series A on Sept. 8 to fund a registrational Phase 2 trial of BCB-276, a B7-H3 CAR T therapy delivered directly into cerebrospinal fluid for DIPG, and to advance a triple-antigen glioblastoma program. The Seattle Children’s spinout aims to bypass the blood-brain barrier with intrathecal delivery after promising early survival signals.
BrainChild Bio raises $116M Series A to fund Phase 2 CAR T trial for childhood DIPG
Seattle startup BrainChild Bio raised $116 million in Series A funding to advance a CAR T cell therapy for diffuse intrinsic pontine glioma (DIPG) and to support development of additional pediatric and adult brain tumor CAR T programs. The financing will fund a pivotal ILLUMINATE Phase 2 registration-stage trial and was led by an undisclosed private family fund and foundation, with participation from Seattle Children’s and WRF Capital.
BrainChild Bio Raises $116M Series A to Fund Phase 2 ILLUMINATE Trial of BCB‑276 for DIPG
BrainChild Bio, a Seattle clinical-stage biotech led by CEO Steven Brugger, raised $116M in a Series A led by an undisclosed private family fund and foundation with participation from Seattle Children’s and WRF Capital to fund Phase 2 ILLUMINATE study of BCB‑276 for DIPG and continued development of BCB‑214 for glioblastoma.
Organizations
-
BrainChild Bio CEO · current
